Published in Cancer Res on February 01, 2006
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J Virol (2009) 1.32
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
Activating and inhibitory FcgammaRs in autoimmune disorders. Springer Semin Immunopathol (2006) 0.96
Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci U S A (2015) 0.94
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc Natl Acad Sci U S A (2006) 0.92
Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatol Res Pract (2010) 0.90
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res (2008) 0.86
Role of Fc Receptors as a therapeutic target. Inflamm Allergy Drug Targets (2009) 0.83
Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance. J Immunol (2013) 0.82
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunol Immunother (2011) 0.82
Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination. J Biol Chem (2015) 0.77
Fc gamma receptors and cancer. Springer Semin Immunopathol (2006) 0.76
Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduct Target Ther (2016) 0.76
Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. J Biol Chem (2016) 0.75
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol Res (2015) 0.75
Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. Theranostics (2017) 0.75
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 3.59
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38
Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med (2009) 3.12
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 2.31
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) 1.79
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med (2002) 1.73
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol (2009) 1.71
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog (2007) 1.61
C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol (2004) 1.57
CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med (2007) 1.57
Crosstalk between human IgG isotypes and murine effector cells. J Immunol (2012) 1.53
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest (2006) 1.51
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol (2008) 1.46
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A (2013) 1.42
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res (2006) 1.39
Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med (2002) 1.39
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol (2004) 1.39
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood (2008) 1.38
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol (2007) 1.38
Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest (2003) 1.37
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol (2011) 1.34
Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 1.31
Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol (2009) 1.31
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res (2008) 1.30
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol (2011) 1.16
Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol (2011) 1.15
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol (2002) 1.14
IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol (2008) 1.14
A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum (2004) 1.10
Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol (2011) 1.10
Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol (2003) 1.10
Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol (2003) 1.10
Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure (2011) 1.10
Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med (2007) 1.09
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol (2008) 1.08
Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell Microbiol (2006) 1.08
C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcgamma receptors. J Immunol (2007) 1.08
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem (2008) 1.08
CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res (2003) 1.07
Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. Blood (2003) 1.05
Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol (2008) 1.04
Renaissance of cancer therapeutic antibodies. Drug Discov Today (2003) 1.04
Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses. PLoS One (2011) 1.04
Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol (2007) 1.02
Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood (2003) 1.01
Fcγ receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1. PLoS Pathog (2010) 1.01
Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol (2005) 1.01
Critical but overlapping role of FcgammaRIII and FcgammaRIV in activation of murine neutrophils by immobilized immune complexes. J Immunol (2008) 1.01
Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum (2009) 1.00
Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol (2008) 1.00
Evidence for non-random distribution of Fcgamma receptor genotype combinations. Immunogenetics (2003) 0.98
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol (2007) 0.96
Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol (2008) 0.96
Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res (2004) 0.95
Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci (2002) 0.94
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol (2012) 0.94
Antibodies trap tissue migrating helminth larvae and prevent tissue damage by driving IL-4Rα-independent alternative differentiation of macrophages. PLoS Pathog (2013) 0.93
Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis. Am J Pathol (2003) 0.92
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc Natl Acad Sci U S A (2006) 0.92
The complex role of Fcgamma receptors in the pathology of arthritis. Springer Semin Immunopathol (2006) 0.91
Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum (2010) 0.91
CD11b limits bacterial outgrowth and dissemination during murine pneumococcal pneumonia. J Infect Dis (2005) 0.91
Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein. J Immunol (2004) 0.91
Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells. J Immunol (2012) 0.91
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs (2014) 0.91
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids (2013) 0.91
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol (2011) 0.90
Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol (2008) 0.90
Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proc Natl Acad Sci U S A (2004) 0.90
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. Neoplasia (2012) 0.90
Retracted The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A (2008) 0.89
Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol Med Microbiol (2006) 0.89
Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions. J Immunol (2013) 0.88